Enrique Ocio, MD, PhD, of Marqués de Valdecilla University Hospital, Santander, Spain, shares his views on when therapy should be initiated for patients with newly diagnosed multiple myeloma, and gives an overview of how the treatment landscape has changed over time. Dr Ocio discusses different types of induction therapies available and how to allocate therapies to patients who will benefit from earlier treatment, commenting on the potential role of biomarkers. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.